KPTI

Karyopharm Therapeutics Inc.

KPTI · CIK 1503802 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$146M
20182025
Net Income−$196M
20182025
Operating CF−$75M
20182025
Free Cash Flow−$75M
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$0.1B$0.1B$0.1B$0.2B$0.2B$0.1B$0.0B$0.0B
Cost of Revenue————————
Gross Profit————————
R&D Expense$0.1B$0.1B$0.1B$0.1B$0.2B$0.2B$0.1B$0.2B
SG&A Expense$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B—
Operating Income$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B$-0.2B$-0.2B$-0.1B
Net Income$-0.2B$-0.1B$-0.1B$-0.2B$-0.1B$-0.2B$-0.2B$-0.1B
EPS (Basic)$-17.93$-0.63$-1.25$-2.02————
EPS (Diluted)$-17.93$-0.93$-1.25$-2.02————

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.1B$0.2B$0.2B$0.4B$0.3B$0.3B$0.3B$0.3B
Current Assets$0.1B$0.2B$0.2B$0.4B$0.3B$0.3B$0.3B$0.3B
Cash & Equivalents$0.1B$0.1B$0.1B$0.1B$0.2B$0.1B$0.1B$0.1B
Total Liabilities$0.4B$0.4B$0.4B$0.4B$0.4B$0.3B$0.2B$0.2B
Current Liabilities$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B
Stockholders' Equity$-0.3B$-0.2B$-0.1B$-0.0B$-0.1B$0.1B$0.0B$0.2B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B$-0.2B$-0.2B$-0.2B
Investing Cash Flow$0.0B$0.1B$0.0B$-0.1B$0.1B$-0.1B$0.1B$-0.1B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.0B$0.0B$0.0B$0.2B$0.1B$0.2B$0.1B$0.3B
← Companies